Tin tức & Cập nhật
Xem bài viết Dược
Xem

Lenzilumab reduces likelihood of survival without ventilation in COVID-19 patients
In hospitalized COVID-19 patients, treatment with the novel GM-CSF* neutralizing monoclonal antibody lenzilumab led to a significant improvement in survival without invasive mechanical ventilation (SWOV), findings from the phase III LIVE-AIR study suggest.

Dapagliflozin improves symptoms, physical limitations in HFpEF
Patients with heart failure and preserved ejection fraction (HFpEF) treated with dapagliflozin experienced improvements in symptoms and physical limitations, according to results of the PRESERVED-HF study presented at HFSA 2021.

Cilostazol makes good in DAPT for recurrent stroke prevention in high-risk patients
Dual antiplatelet therapy (DAPT) with cilostazol performs better than either aspirin or clopidogrel alone at reducing the risk of recurrent stroke or vascular events without increasing the incidence of bleeding for patients with ischaemic stroke and intracranial arterial stenosis, according to the results of the CSPS.com* trial.

Older age, CRP portend deaths in COVID-19 patients with diabetes
Older age and elevated levels of the inflammatory marker C-reactive protein (CRP) may predict mortality in COVID-19 patients, particularly if coupled with diabetes, the retrospective ACCREDIT study has shown.

Ticagrelor after abbreviated DAPT minimizes bleeding while preserving efficacy in ACS
Monotherapy with ticagrelor after a month-long course of dual antiplatelet (DAPT) with ticagrelor plus aspirin works to reduce the risk of bleeding without compromising ischaemic outcomes among patients with acute coronary syndrome (ACS) as compared with guideline-recommended treatment with 12-month DAPT followed by aspirin monotherapy, according to data from the GLOBAL LEADERS trial.




